The FDA said the updated messenger RNA vaccines from Pfizer/BioNTech and Moderna will protect against the omicron subvariants now prevalent in circulation. Left out of the FDA decision is Novavax, whose protein-based vaccine is still under regulatory review.
The post FDA Approves Updated COVID-19 Vaccines To Address Now Circulating Variants appeared first on Above the Law.
Citing “political challenges” within the American Bar Association, and reportedly out of fear of budget cuts or even its own shutdown, the ABA’s Center for…
GSK claims that Pfizer’s FDA-approved vaccine for respiratory syncytial virus infringes on four patents protecting its own approved vaccine, Arexvy. The patent suit comes with…
By Guest Bloggers Margaret Chon and Christine Haight Farley [Margaret Chon is a Professor of Law at Seattle University School of Law, and Christine Haight…
[Note: this post does NOT cover the Fifth Circuit’s ruling in Missouri v. Biden, which also addressed government jawboning regarding COVID misinformation. Missouri v. Biden,…
When the government tells you, a private enterprise, that it would really like you to do something, the “or else” is always implied. “Nice internet…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Responses